Clinical trials: Mass Drug Administration
Malignant Tumor of Cervix, Cervical Intraepithelial Neoplasia
Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General Practitioner
This study evaluates the benefit in women aged from 30 to 65 years, who do not participate to the French opportunistic cervical cancer screening program, of an organized screening with the proposition by the family physician of a…
- Trial name
- PaCUDAHL-Gé (NCT02749110)
- Testing
- Vaginal self-sampling brush
- Where
- France
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Malaria, Falciparum
Mass-Drug Administration to Reduce Malaria Transmission
In the 1950s, the WHO included mass drug administration (MDA) with antimalarial drugs as a tool for malaria control in 'exceptional conditions when conventional control strategies have failed'.
- Trial name
- MDATRANS (NCT00509015)
- Testing
- Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Artesunate (day 1,2,3: 4 mg/kg), Primaquine-base (day 3: 0.75 mg/kg)
- Where
- Tanzania
- Volunteers
- 6,000 people
- Sponsor
- Radboud University Medical Center
Plasmodium Falciparum Malaria
Mass Vaccine and Drug Administration, Bangladesh
This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass…
- Trial name
- MVDA (NCT06068530)
- Testing
- DHA/piperaquine and a SLD-PQ, Study vaccine R21/Matrix-M™
- Where
- 2 sites in Bangladesh
- Volunteers
- 10,000 people
- Sponsor
- University of Oxford
Malaria, Lymphatic Filariasis
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in…
- Trial name
- RIMDAMAL (NCT02509481)
- Testing
- Ivermectin, Albendazole
- Where
- 2 sites in United States, Burkina Faso
- Volunteers
- 2,712 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Scabies, Yaws
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
This is an open-label prospective community intervention trial to assess the impact of community mass treatment with azithromycin for yaws and ivermectin for scabies, on non-yaws bacterial skin infections.
- Conditions
- Scabies, Yaws, Impetigo
- Trial name
- AIM-Skin (NCT02775617)
- Testing
- Ivermectin, Azithromycin, Permethrin
- Where
- Solomon Islands
- Volunteers
- 1,291 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Helminth Infection
Intestinal Microbiome Post-Azythromycin/Albendazole Treatment
Molecular testing of the gut microbiome and enteric pathogens is rapidly moving beyond targeted PCR testing to next generation sequencing techniques.
- Trial name
- NCT03032042
- Testing
- Azithromycin, Albendazole, Delayed treatment
- Where
- Ethiopia
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Child Mortality, Azithromycin
Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire
The aim of the study is to gather preliminary evidence on the operational feasibility and acceptability of integrating bi-annual mass drug administration (MDA) of single-dose azithromycin for children ages 1 to 11 months in high…
- Trial name
- REACH (NCT04617626)
- Testing
- Azithromycin
- Where
- Côte d’Ivoire
- Volunteers
- 1,735 people, healthy volunteers welcome
- Sponsor
- FHI 360
Mortality
Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali
The LAKANA trial will assess the impact on mortality and other health outcomes of quarterly and biannual azithromycin mass drug administration (MDA) when delivered to 1-11-month (29-364 days) old infants in a high-mortality…
- Trial name
- LAKANA (NCT04424511)
- Testing
- Azithromycin
- Where
- Mali
- Volunteers
- 149,201 people, healthy volunteers welcome
- Sponsor
- Tampere University
Lymphatic Filariasis, Onchocerciasis
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Approximately 5,200 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas.
- Conditions
- Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections
- Trial name
- DOLF-LIBERIA (NCT01905436)
- Testing
- Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
- Where
- Liberia
- Volunteers
- 21,862 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis
East New Britain Province Monitoring & Evaluation
While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a public health problem by 2020…
- Conditions
- Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis, Acceptability of Mass Drug Administration for Lymphatic Filariasis
- Trial name
- ENBP M&E (NCT04124250)
- Testing
- Observational
- Where
- Papua New Guinea
- Volunteers
- 12,930 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Lymphatic Filariasis, Soil Transmitted Helminth Infections
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Approximately 3,500 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis endemic areas. The study will be performed in Indonesia in B. timori and W.
- Trial name
- DOLF-Indo (NCT01905423)
- Testing
- Albendazole (annual), Diethylcarbamazine (annual), Albendazole (semiannual)
- Where
- Indonesia
- Volunteers
- 17,108 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Malaria
Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)
The BOHEMIA program consists of a combination of studies organized around a central community prevention mass drug administration protocol and four sub-studies (i.e.; social science, entomology, health economics, and…
- Trial name
- BOHEMIA (NCT04966702)
- Testing
- Albendazole Pill, Ivermectin Pill, Ivermectin Injectable Product
- Where
- 2 sites in Kenya, Mozambique
- Volunteers
- 48,145 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Obesity, Overweight
Teaching Obesity Treatment Options to Adult Learners (TOTAL): A Multisite RCT
Nearly 8 in 10 Veterans meet criteria for overweight/obesity. Three evidence-based treatment options are available within VA (behavioral weight management [MOVE!], obesity medications, and bariatric surgery).
- Trial name
- TOTAL (NCT05346575)
- Testing
- Teaching Obesity Treatments to Adult Learners (TOTAL), Usual care
- Where
- 2 sites in United States
- Volunteers
- 440 people
- Sponsor
- VA Office of Research and Development
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Ribociclib (LEE011) Rollover Study for Continued Access
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011)…
- Trial name
- NCT02934568
- Testing
- LEE011
- Where
- 13 sites in United States, France and 4 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +/- Reactive Focal Vector Control (RAVC) in Namibia
This is a cluster randomised controlled trial with factorial study design comparing the impact of reactive community-based malaria interventions: 1) presumptive treatment (or rfMDA, reactive focal mass drug administration) versus…
- Trial name
- NCT02610400
- Testing
- RACD, RAVC, rfMDA
- Where
- Namibia
- Volunteers
- 9,845 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Neonatal Abstinence Syndrome
Interest of Concentrations in Meconium of Buprenorphine and Methadone as a Prognostic Factor of NAS Outcome
The aim of this study is to characterize the interest of concentrations in meconium of drugs used for treatment of pregnant opioid-dependent woman as a prognostic factor of time, severity and duration of neonatal abstinence…
- Trial name
- SUBOPGEST (NCT03334981)
- Testing
- Concentrations in Meconium of Buprenorphine and Methadone
- Where
- France
- Volunteers
- 92 people
- Sponsor
- University Hospital, Caen
Helminthiasis, Filariasis
Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Over 1.5 billion people are infected with soil-transmitted helminths (STH). Global STH guidelines recommend MDA (mass drug administration) of albendazole or mebendazole to targeted populations, including pre-school age children…
- Trial name
- NCT03014167
- Testing
- Albendazole
- Where
- 3 sites in Benin, India and 1 more
- Volunteers
- 357,716 people, healthy volunteers welcome
- Sponsor
- University of Washington
Lymphatic Filariasis, Scabies
Better Options for Lymphatic Filariasis Treatment
The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and…
- Conditions
- Lymphatic Filariasis, Scabies, Strongyloidiasis
- Trial name
- BOLT (NCT07159373)
- Testing
- MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole
- Where
- Fiji
- Volunteers
- 5,100 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Trachoma, Chlamydia
Trachoma Amelioration in Northern Amhara (TANA)
The WHO has initiated a program to eliminate trachoma, blinding eye infection caused by Chlamydia trachomatis, in large part by mass distributions of oral azithromycin.
- Trial name
- TANA (NCT00322972)
- Testing
- Mass treatment with oral azithromycin to an entire community
- Where
- Ethiopia
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Childhood Obesity
The Healthy Lifestyles Passport Program: a Nutrition Education Program to Prevent Childhood Obesity
The purpose of this study is to evaluate the effectiveness of the Healthy Lifestyles Passport Program (HLPP) in preventing infant and childhood obesity.
- Trial name
- HLPP (NCT01649115)
- Testing
- Healthy Lifestyles Passport
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Bronx-Lebanon Hospital Center Health Care System